olivLaw · European equity research
Genflow Biosciences PLC GENF.L
United Kingdom · London Stock Exchange · ISIN GB00BP2C3V08 · Vertical: Listed companies from United Kingdom
Genflow Biosciences is a preclinical biotechnology company developing gene therapies based on a centenarian variant of SIRT6, aiming to slow ageing processes and related diseases. The company is preparing preclinical studies and depends on regional grants and new funding, with cash and cash equivalents of £111,792 at the end of 2025.
At the close of 05 Nov 2026, Genflow Biosciences PLC (GENF.L) stock was 0.02 GBP (+0.00% on the day), with market capitalisation 77.9 k GBP, beta 0.05, 52-week range 0.02–0.03 GBP.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 46.4
- neutral
- Bollinger (20, 2)
- 0.02 – 0.02
- in the upper half of the band · %B 0.60 · band width 9.4%
- SMA 50 / 200
- 0.02 / 0.02
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.00 / -0.00
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +4.3% | −0.6% | +4.9 pp | — |
| 3 months | +1.4% | −4.2% | +5.6 pp | — |
| 6 months | −29.8% | +4.3% | −34.1 pp | — |
| Year to date | −1.4% | +7.5% | −8.9 pp | — |
| 1 year | −12.0% | +9.9% | −22.0 pp | +6.7% |
| 3 years | +14.1% | +49.8% | −35.8 pp | +24.8% |
| 5 years | unavailable | +42.8% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | -1.9 m | -1.6 m | -1.4 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.48 | -0.33 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable |
| Free cash flow | -1.7 m | -1.1 m | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 111.8 k GBP
- Financial debt
- unavailable GBP
- Net debt
- unavailable GBP
- Equity
- -550.8 k GBP
- Total assets
- 452.4 k GBP
- Debt / equity
- unavailable
- Current ratio
- unavailable
- ROE
- unavailable
- ROA
- -338.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (GBP)
Income statement · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Gross profit | — | 320.5 k | 585.6 k | esef· 27 May 2026verified |
| Operating income | — | -1.6 m | -1.4 m | esef· 27 May 2026verified |
| Pre-tax income | -1.9 m | -1.6 m | -1.4 m | esef· 27 May 2026verified |
| Income tax | 0 | 0 | 0 | esef· 27 May 2026verified |
| Net income | -1.9 m | -1.6 m | -1.4 m | esef· 27 May 2026verified |
| Diluted EPS | — | -0.48 | -0.33 | esef· 27 May 2026verified |
Balance sheet · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 684.0 k | 278.7 k | 111.8 k | esef· 27 May 2026verified |
| Receivables | 384.3 k | 105.2 k | 339.5 k | esef· 27 May 2026verified |
| Current assets | 1.1 m | 383.8 k | 451.3 k | esef· 27 May 2026verified |
| Property, plant & equipment, net | 3.4 k | 2.1 k | 1.1 k | esef· 27 May 2026verified |
| Total assets | 1.1 m | 385.9 k | 452.4 k | esef· 27 May 2026verified |
| Accounts payable | 572.0 k | 788.9 k | 1.0 m | esef· 27 May 2026verified |
| Total liabilities | 572.0 k | 788.9 k | 1.0 m | esef· 27 May 2026verified |
| Equity | 499.7 k | -403.0 k | -550.8 k | esef· 27 May 2026verified |
| Shares outstanding at year end | — | 3.3 m | 4.3 m | esef· 27 May 2026derived |
Cash flow · GBP
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -1.7 m | -1.1 m | -1.4 m | esef· 27 May 2026verified |
| Capex | 2.4 k | 0 | — | esef· 13 May 2025verified |
| Free cash flow | -1.7 m ≈ | -1.1 m ≈ | — | esef· 13 May 2025derived |
| Investing cash flow | -2.4 k | 0 | 0 | esef· 27 May 2026verified |
| Financing cash flow | 0 | 656.6 k | 1.3 m | esef· 27 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 1 of at least 6
- score weight coverage: 8.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 77.9 k GBP
Key indicators
Coverage and freshness
Score by group
8% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 1 of at least 6; score weight coverage: 8.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | unavailable | unavailable | — |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -1,843.6% | 0 (on a fixed band) | 100% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partialunavailable · 0/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GENFLOW BIOSCIENCES PLC (GENF.L). Latest full fiscal year: 2025; data up to 2025-12-31.
Financial indicators are unavailable.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 1 of at least 6; score weight coverage: 8.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- FCF yield: -1,843.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, Current ratio, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 40 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| BMS.LBraemar PLC | 78.3 m | 39.2 | 2.7% | 1.7% | −4.4% | +13% / −11% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
1- and 3-year price returns: for GENF.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Genflow Biosciences is a preclinical biotechnology company developing gene therapies based on a centenarian variant of SIRT6, aiming to slow ageing processes and related diseases. The company is preparing preclinical studies and depends on regional grants and new funding, with cash and cash equivalents of £111,792 at the end of 2025.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Dependence on the exclusive licencehigh
If the licence with the University of Rochester were terminated or obligations were not met, operations could be materially affected 1.
- Dependence on key personnelmedium
The company relies on the experience of a few key executives and advisers, and replacing them could be difficult 1.
- Conditional grantslow
Regional funding depends on reaching specific milestones, and failing them could reduce available funds 1.
Investment thesis
What would need to be true (bull case)
- If preclinical data and the canine study confirm the SIRT6 hypothesis, the company could hold a first-mover position in several markets without approved therapies 1.
- Interest from animal health partners could generate revenue ahead of the human programmes, easing funding pressure 1.
- The patent portfolio and regional grants could support broader collaborations with leading partners 1.
What would break the thesis
- The company has no completed clinical study and remains dependent on external funding, which could limit programme progress 1.
- A negative result in preclinical studies could affect several programmes at once, given their common platform 1.
- Concentrated shareholding in one substantial holder and dependence on the exclusive licence could create governance vulnerabilities 1.
What to watch
- Interim and final results of the canine trial and efficacy data2026
- IND filing for GF-1002 and start of the first-in-patient proof-of-concept study in MASH2026
- New equity raises and receipt of the remaining Walloon grant balancenext 10-K
- Agreements with animal health companies currently in confidential discussion2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Genflow Biosciences PLC is a preclinical biotechnology company developing innovative biological interventions, mainly gene therapies, meant to address the effects of ageing and reduce the incidence of age-related diseases 1. Its activity centres on the centenarian SIRT6 enzyme variant, delivered through non-viral mRNA/LNP platforms, with applications in human and companion animal health. The loss from continued operations was £1,417,564 in 2025 and no dividend was recommended 1.
The strategy spans four programmes: MASH (GF-1002), sarcopenia (GF-1005), glaucoma (GF-1006) and animal health, alongside the LNP/mRNA platform 1. For each programme the company pursues concrete milestones, such as an IND filing for GF-1002 or completing the canine trial, without yet having an approved product 1.
Funding comes from Walloon government grants, equity raises and academic and industry collaborations, including with the Université libre de Bruxelles and IRIS Pharma 1. The company states it will need additional capital for clinical studies and commercialisation 1.
Segments
Sarcopenia (GF-1005)
The programme targets age-related muscle loss, for which no approved drug exists, by restoring mitochondrial health in muscle progenitor cells 1. The company states that prevalence rises sharply after 70, making it a strategically important direction 1.
Market context
The global glaucoma therapeutics market is valued at about 9 billion USD, with projections of 12–14 billion USD by the early 2030s, according to the company's report 1. In sarcopenia the company notes that no pharmacological therapy is approved, leaving room for a first mover 1.
Growth in these markets is supported by ageing populations and by the limits of current treatments, which do not address neuronal or muscle degeneration 1. Actual access, however, depends on clinical results, and human clinical studies have not yet started 1.
Trends
- Ageing populationtailwind
A growing elderly population expands demand for treatments against sarcopenia and glaucoma, which could support interest in the company's programmes 1.
- Interest in companion animal healthtailwind
Wider pet ownership and demand for advanced veterinary interventions open a nearer-term market for the canine programme 1.
- Cost and duration of clinical trialsheadwind
Clinical studies are expensive and long, and the company acknowledges it will need to raise further funds to complete them 1.
- Regional grants and support schemesmixed
Walloon grants, conditional on milestones, offer non-dilutive funding but depend on meeting objectives 1.
Competitive position
The analysed sources do not name competitors in the company's report, but the company notes that glaucoma treatments currently focus on lowering intraocular pressure and that no approved sarcopenia therapy exists 1. Its competitive position rests on intellectual property and the centenarian SIRT6 variant, which the company regards as a barrier to competition 1.
In animal health the company says it is in discussions with several industry partners, without naming them, so the competitive landscape remains unclear from the source 1. Direct competition in gene therapy is not detailed in the report 1.
- Makers of glaucoma drugs based on prostaglandin analogues and beta-blockers
Current standard-of-care treatments that lower intraocular pressure are described but not named in the source; no confident ticker 1.
- Animal health companies in confidential discussions
The company mentions confidential discussions under a CDA without identifying the parties 1.
- LNP technology providers
The company plans to expand collaborations with top-tier LNP companies, not named in the source 1.
- GMP contract manufacturing organisations
A selected CDMO handles the MASH clinical lot, not named in the source 1.
News & filings
In the press
- Ilika, Genflow, EnergyPathways, Ariana Resources, Tertiary Minerals, Light Science TechnologiesYahoo Finance — News · 11 Sept 2026 · EN
Annual reports (ESEF)
- Annual report 202527 May 2026
- Annual report 202413 May 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / Genflow Biosciences PLC · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.